SecBot SecBot
SECBOTREPLAY Home › Report › SPRO

SPRO · Spero Therapeutics filed additional proxy materials for its 2026 Annual…

Spero Therapeutics, Inc. · DEFA14A filed Apr 27, 2026 at 16:39 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Apr 27, 2026 at 16:39 ET

Spero Therapeutics filed additional proxy materials for its 2026 Annual Meeting, scheduled for June 23, 2026. Proposals include electing two Class III directors, ratifying the auditor, advisory vote on executive compensation, doubling authorized shares from 120M to 240M, and adopting a new stock incentive plan. The board recommends a 'For' vote on all items.

  • Annual meeting set for June 23, 2026
  • Proposal to increase authorized common shares from 120,000,000 to 240,000,000
  • Proposal to adopt the 2026 Spero Therapeutics, Inc. Stock Incentive Plan
  • All five proposals are recommended 'For' by the board

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access